Novel coronavirus multi-epitope recombinant antigen and preparation method thereof
A technology for recombinant antigens and coronaviruses, applied in biochemical equipment and methods, viruses, viral peptides, etc., can solve the problems of being unable to be used in a large area by grassroots medical institutions, demanding requirements, and long detection time, so as to eliminate the risk of false positives, The effect of improving specificity and enhancing recognition ability
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0017] Example 1: Selection of novel coronavirus dominant antigenic epitopes
[0018] The biological software DNAstar was used to analyze the hydrophilicity, hydrophobicity and antigenicity of the epitope sequences of S, E, and M antigens of the novel coronavirus, and the dominant epitopes of the S antigen (SEQ ID No: 2) and the dominant epitopes of the E antigen (SEQ ID No: 2) were respectively selected. ID No:3) and M antigen dominant epitope (SEQ ID No:4). At the same time, the sequence comparison results showed that the selected dominant antigenic epitope had high sequence specificity and had no obvious homology with other antigenic sequences other than coronavirus antigens.
Embodiment 2
[0019] Example 2: S, E, M antigen dominant epitope tandem
[0020] In order to enhance the ability of the recombinant antigen to recognize the new coronavirus antibody, the dominant epitopes of the S, E, and M antigens were connected through a flexible fragment (GlyGlyGlyGlySer), and a His tag was added to the carbon-terminus of the sequence to obtain the amino acid sequence of the recombinant antigen. The specific sequence is as follows: The sequence listing is shown in SEQ ID No:1.
Embodiment 3
[0021] Example 3: Optimizing the Nucleotide Sequence Encoding the Recombinant Antigen
[0022] In order to increase the expression of recombinant antigen, under the premise that the amino acid sequence of the recombinant antigen remains unchanged, the amino acid sequence encoding the recombinant antigen is converted into the corresponding nucleotide sequence according to the preferred codons of CHO cells. The specific sequence is shown in the sequence table SEQ ID No: 5. shown, and the nucleotide sequences corresponding to the enzyme cutting sites EcoRI and BamHI were added to the upstream and downstream respectively, and synthesized by Hangzhou Xianzhi Biotechnology Co., Ltd. The synthesized target gene was cloned in the pMD19-T vector (Bao Bioengineering Dalian Co., Ltd.).
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com